In SPF email authentication, a TXT record published in the DNS on your domain is used to check if a new email message that reaches your recipient’s email server comes from an authorized sending source. In order to allow SPF authentication to pass for emails that you send via Act-on, you need to add an SPF record to Act-on. But before that, you need to add the email addresses from which you will send authorized mails to the ‘Send From’ email list.
Adding an email address to the ‘Send From’ list in Act-on
- Login through Admin account.
- Go to Settings > Other Settings > From: Addresses.
- Click on the Add From: Address button at the bottom.
- Enter a Display Name and Email Address from which you need to send emails from.
- Click on Add Now button to add the email address to the list.
- Go to the inbox of the email address, and click on the verification mail to complete this process.
Creating an SPF Record for Act-on
Here are the steps to set up SPF for Act-on :
- Login to your DNS management console
- Navigate to Tools & Settings > DNS Template
- You need to edit the DNS TXT record related to SPF
- An SPF TXT record for Act-on will have the following syntax:
mydomain.com TXT v=spf1 include:_spf.act-on.net -all - Publish this record in your DNS records section for your respective domain.
Note: If you don’t have an SPF record previously for your domain, simply publish the above-mentioned record to enable SPF for outgoing emails using Act-on. If you do have an existing SPF record in your DNS, you need to modify it to include Acy-on, as shown below:
Previous SPF record: v=spf1 mx -all
Modified SPF record: v=spf1 mx include:_spf.act-on.net -all
- Save changes
- Wait for 72 hours to allow your DNS to process the changes
After publishing the records through DNS, fill this form to contact Act-on Support at the bottom of this page.
(Note: You will have to set up both SPF and DKIM before submitting the form)
Finally, you can look up your record using our SPF record lookup tool, and enable DMARC for your domains: take a DMARC trial.
